New drug offers hope for AF patients too risky for standard blood thinners
Disease control
Recruiting now
This study is testing whether a new drug called abelacimab can safely prevent strokes and other blood clots in people with atrial fibrillation (AF) who are at high risk but cannot take standard blood-thinning pills. About 1,900 participants will receive either abelacimab or a pla…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 02:12 UTC